---
layout: default
title: Alpha -Tocopherol Acetate Dl- Ascorbic Acid Cholec
parent: 僅模型預測 (L5)
nav_order: 235
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Acetate Dl- Ascorbic Acid Cholec
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Vitamin Combination: Insufficient Data for TxGNN Repurposing Prediction

## One-Sentence Summary

This submission contains a 12-component vitamin and micronutrient combination (.alpha.-Tocopherol Acetate, Ascorbic Acid, Cholecalciferol, Levomefolate Calcium, Methylcobalamin, Niacin, Pyridoxine HCl, Riboflavin, Sodium Ascorbate, Sodium Fluoride, Thiamine Mononitrate, Vitamin A) with no Taiwan regulatory registration.
The TxGNN model did **not generate any repurposing predictions** for this formulation, as the multi-ingredient string could not be resolved to a single DrugBank node required for model input.
Without a prediction anchor, downstream evidence collection and decision analysis cannot proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no TFDA registration record found |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | — (below L5; model produced no output) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN model operates on individual DrugBank-mapped compounds. This submission's drug identifier is a semicolon-delimited list of **12 distinct active ingredients**, which the pipeline cannot resolve to a single DrugBank ID (confirmed `drugbank_id: null`).

As a result:
1. **DrugBank mapping failed** — the query returned a result count of 1 (likely a partial or ambiguous hit), but no stable ID was extracted.
2. **KG node unavailable** — without a DrugBank node, neither the Knowledge Graph nor the Deep Learning model can generate a score.
3. **Evidence collection was never triggered** — clinical trials and literature queries require a valid predicted indication to anchor the search.

This is a **pipeline input error**, not a scientific finding about the combination's repurposing potential.

---

## US Market Information

No Taiwan (TFDA) authorisations were found for this multi-ingredient combination as a single registered product.

> Individual components (e.g., Cholecalciferol, Ascorbic Acid, Vitamin A) are widely available as separately registered products. This combination as a unified dosage form has no records in the queried database.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline requires a single, DrugBank-resolvable compound as input; this 12-ingredient combination cannot be processed as submitted, and no repurposing prediction was generated. There is no scientific output to evaluate.

**To proceed, the following is needed:**

- **Decompose the query**: Submit each of the 12 active ingredients individually through the TxGNN pipeline (e.g., Cholecalciferol → DB00169, Methylcobalamin → DB00116). Aggregate and cross-reference the resulting predictions.
- **Identify the lead ingredient**: Determine which component is the primary therapeutic agent for the intended new indication, and anchor the repurposing hypothesis to that single compound.
- **Confirm the intended indication**: Clarify whether this formulation is a prenatal supplement, a nutritional deficiency treatment, or another category — this will focus the evidence search.
- **Resolve TFDA gap**: Download and parse the TFDA package insert PDF for any registered single-ingredient versions to populate safety warnings and contraindications (currently blocking per DG001).
- **DrugBank MOA lookup**: Query each ingredient's DrugBank record individually to populate mechanism of action (DG002).
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

